Evaluation of Direct-Acting Antiviral (DAA) Regimens on hepatitis C.

Phase 3

Recruiting

• Conditions: Hepatitis C.; Chronic viral hepatitis C; B18.2

• Registration Number: IRCT20081110001444N7
• Lead Sponsor: Yazd University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 8 March 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 51

Inclusion Criteria

Adults (= 18 years)
regardless of their previous treatment or stage of liver fibrosis

Exclusion Criteria

The patients who took drugs including carbamazepine, phenytoin, rifampin, phenobarbital, antacids and rosuvastatin
had a history of taking amiodarone in the past three months
those with severe renal insufficiency
pregnant women
patients with no high life expectancy due to other diseases

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Sustained virological response. Timepoint: After 12 weeks. Method of measurement: Polymerase Chain Reaction (PCR).